The association of EZH2 overexpression with both gene-specific and global hypermethylation has been described before for prostate cancer, small cell lung carcinoma and cell sarcoma of the kidney, suggesting the role of this histone modifier in directing hypermethylation [57,58,59]. Here, EZH2 is linked to prostate carcinoma.